StockNews.com Upgrades Moleculin Biotech (NASDAQ:MBRX) to “Sell”

StockNews.com upgraded shares of Moleculin Biotech (NASDAQ:MBRX) to a sell rating in a research note published on Wednesday.

A number of other brokerages have also recently issued reports on MBRX. Maxim Group upgraded Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Moleculin Biotech in a research report on Monday, March 24th.

Moleculin Biotech Trading Down 1.0 %

MBRX opened at $1.04 on Wednesday. The business’s 50-day simple moving average is $1.29 and its 200 day simple moving average is $1.98. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $6.09.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.